Small molecule · developed by Glaxosmithkline
Tafenoquine is an 8-aminoquinoline antimalarial drug.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jan 10, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06656351 | Phase 2 | Chronic Babesiosis | Recruiting | SXTP |
| NCT06207370 | Phase 2 | Babesiosis | Recruiting | SXTP |
| NCT04533347 | Phase 2 | COVID 19 Disease | Completed | SXTP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
BabesiosisChronic BabesiosisCOVID 19 Disease
Updated Nov 1, 2026.